Adial Financial Statements From 2010 to 2024

ADIL Stock  USD 1.00  0.01  0.99%   
Adial Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Adial Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Adial Pharmaceuticals financial statements helps investors assess Adial Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Adial Pharmaceuticals' valuation are summarized below:
Market Capitalization
6.5 M
Earnings Share
(2.94)
There are over one hundred nineteen available fundamental signals for Adial Pharmaceuticals, which can be analyzed over time and compared to other ratios. We recommend to validate Adial Pharmaceuticals' prevailing fundamental drivers against the all of the trends between 2010 and 2024. The value of Market Cap is estimated to slide to about 5 M. The Enterprise Value is projected to slide to about 2.2 M
Check Adial Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adial Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 111.6 K, Depreciation And Amortization of 616 or Interest Expense of 758.1 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.68. Adial financial statements analysis is a perfect complement when working with Adial Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Adial Pharmaceuticals Correlation against competitors.
For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.

Adial Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.4 M4.7 M2.8 M
Slightly volatile
Other Current Liabilities761.2 K525.7 K448.2 K
Slightly volatile
Total Current Liabilities1.1 M653.1 K676.7 K
Slightly volatile
Accounts Payable121 K127.4 K166.3 K
Slightly volatile
Cash3.4 M2.8 M2.2 M
Slightly volatile
Non Current Assets Total1.6 M1.5 M371.3 K
Slightly volatile
Other Assets422.6 K402.5 K196.1 K
Slightly volatile
Cash And Short Term Investments3.4 M2.8 M2.2 M
Slightly volatile
Common Stock Total Equity12.3 K13 K4.5 M
Slightly volatile
Common Stock Shares Outstanding1.5 M1.4 M491.2 K
Slightly volatile
Liabilities And Stockholders Equity4.4 M4.7 M2.8 M
Slightly volatile
Other Current Assets370.5 K371.6 K241.2 K
Slightly volatile
Total Liabilities620.4 K653.1 K773.7 K
Slightly volatile
Total Current Assets3.9 M3.2 M2.5 M
Slightly volatile
Short Term Debt242.5 K130.7 K113.5 K
Pretty Stable
Intangible Assets3.7 K3.9 K67.4 K
Slightly volatile
Common Stock1.6 K1.7 K4.5 M
Slightly volatile
Short and Long Term Debt Total277.6 K186.6 K268.6 K
Very volatile
Net Receivables28.1 K31.6 K34.4 K
Slightly volatile
Short and Long Term Debt507.9 K792.7 K471.7 K
Slightly volatile
Capital Stock17.4 K30.7 K12.2 K
Slightly volatile
Other Liabilities829.9 K933.7 KM
Slightly volatile
Current Deferred Revenue1.9 M2.1 M2.3 M
Slightly volatile
Non Current Liabilities Other602.4 K442.8 K913.7 K
Slightly volatile
Property Plant Equipment243.5 K273.9 K298.3 K
Slightly volatile

Adial Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income111.6 K106.2 K28.7 K
Slightly volatile
Depreciation And Amortization61664910.6 K
Pretty Stable
Selling General Administrative5.1 M5.6 M3.3 M
Slightly volatile
Other Operating Expenses8.1 M6.9 M5.2 M
Slightly volatile
Research Development1.2 M1.3 M1.8 M
Slightly volatile
Total Operating Expenses8.1 M6.9 M5.2 M
Slightly volatile
Reconciled Depreciation73.1 K69.6 K17.6 K
Slightly volatile
Selling And Marketing Expenses451508553
Slightly volatile

Adial Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings21.4 K22.5 K127.9 K
Slightly volatile
Stock Based Compensation2.3 M1.7 M1.5 M
Slightly volatile
Begin Period Cash Flow3.2 MM2.2 M
Slightly volatile
Depreciation5365648.2 K
Slightly volatile
Total Cash From Financing ActivitiesM4.1 M3.7 M
Slightly volatile
End Period Cash Flow3.4 M2.8 M2.2 M
Slightly volatile
Change To Netincome7.2 M6.8 M2.7 M
Slightly volatile
Issuance Of Capital Stock712.4 K749.9 K6.1 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables232.7 K181.7 K242.4 K
Pretty Stable
Capex To Depreciation11.4 K10.9 K2.3 K
Slightly volatile
Payables Turnover0.00420.00440.0367
Slightly volatile
Cash Per Share1.891.98534.5185
Slightly volatile
Days Payables Outstanding84.6 K82.4 K77.1 K
Slightly volatile
Income Quality0.510.97210.6086
Slightly volatile
Intangibles To Total Assets8.0E-48.0E-40.048
Very volatile
Current Ratio4.464.89794.9368
Pretty Stable
Graham Number16.9217.811835.6529
Slightly volatile
Capex Per Share4.524.30.9762
Slightly volatile
Average Receivables14 K15.8 K17.2 K
Slightly volatile
Interest Debt Per Share0.05840.06151.2803
Pretty Stable
Debt To Assets0.01080.01142.0564
Pretty Stable
Days Of Payables Outstanding84.6 K82.4 K77.1 K
Slightly volatile
Ebt Per Ebit1.21.01651.0698
Pretty Stable
Quick Ratio4.464.89794.9368
Pretty Stable
Net Income Per E B T0.80.90.9775
Slightly volatile
Cash Ratio3.84.32894.1201
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.810.90.9854
Slightly volatile
Debt Ratio0.01080.01142.0564
Pretty Stable

Adial Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapM5.3 M19.5 M
Pretty Stable
Enterprise Value2.2 M2.4 M17.4 M
Slightly volatile

Adial Fundamental Market Drivers

Cash And Short Term Investments2.8 M

Adial Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Adial Pharmaceuticals Financial Statements

Adial Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Adial Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.1 M1.9 M
Cost Of Revenue 564.00  535.80 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports:
Check out the analysis of Adial Pharmaceuticals Correlation against competitors.
For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.94)
Return On Assets
(1.04)
Return On Equity
(3.21)
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.